Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 3. Biomarkers of biological effect

Biomarkers

Volumn 20, Issue 6-7, 2015, Pages 404-410

  Ogden, Michael W ^a   Marano, Kristin M ^a   Jones, Bobbette A ^b   Morgan, Walter T ^b   Stiles, Mitchell F ^b  

^a RAI Services Company   (United States)

^b R J REYNOLDS TOBACCO COMPANY   (United States)

Author keywords

Inflammation; multi center randomized study; oxidative stress; risk continuum

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; ISOPROSTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; AUTACOID; LIPID; NICOTINE GUM;

ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DNA DAMAGE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; ISOMER; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; MULTICENTER STUDY; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SMOKING; SNUS; TOBACCO; TOBACCO HEATING CIGARETTE; TRIACYLGLYCEROL BLOOD LEVEL; ADULT; BLOOD; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; PREVENTION AND CONTROL; PROCEDURES; SMOKELESS TOBACCO; SMOKING CESSATION; TIME FACTOR; URINE; UTILIZATION;

ADULT; BIOMARKERS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LIPIDS; MALE; MIDDLE AGED; SMOKING; TIME FACTORS; TOBACCO USE CESSATION; TOBACCO USE CESSATION PRODUCTS; TOBACCO, SMOKELESS;

EID: 84948715659     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2015.1094135     Document Type: Article

References (34)

1. Adhikari B, Kahende J, Malarcher A, et al. (2008). Smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 2000-2004. MMWR 57: 1226-8
2. Bolinder G, Norén A, de Faire U, Wahren J. (1997). Smokeless tobacco use and atherosclerosis: an ultrasonographic investigation of carotid intima media thickness in healthy middle-aged men. Atherosclerosis 132: 95-103
3. Borgerding MF, Bodnar JA, Curtin GM, Swauger JE. (2012). The chemical composition of smokeless tobacco: a survey of products sold in The United States in 2006 and 2007. Regul Toxicol Pharmacol 64: 367-87
4. Calapai G, Caputi AP, Mannucci C, et al. (2009). A cross-sectional investigation of biomarkers of risk after a decade of smoking. Inhal Toxicol 21: 1138-43
5. Eliasson M, Lundblad D, Hägg E. (1991). Cardiovascular risk factors in young snuff-users and cigarette smokers. J Intern Med 230: 17-22
6. Frost-Pineda K, Liang Q, Liu J, et al. (2011). Biomarkers of potential harm among adult smokers and nonsmokers in The total exposure study. Nicotine Tob Res 13: 182-93
7. Hatsukami DK, Benowitz NL, Rennard SI, et al. (2006). Biomarkers to assess The utility of potential reduced exposure tobacco products. Nicotine Tob Res 8: 600-22
8. Goto K, Maeda S, Kano Y, Sugiyama T. (1978). Factors involved in differential Giemsa-staining of sister chromatids. Nature 251: 156-8
9. Henley SJ, Connell CJ, Richter P, et al. (2007). Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tob Control 16: 22-8
10. International Conference on Harmonization (ICH). (1996). Guidance for industry E6 good clinical practice: consolidated guidance. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073122.pdf [last accessed 2 Aug 2014]
11. Kondo T, Hayashi M, Takeshita K, et al. (2004). Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol 24: 1442-7
12. Latt SA. (1974). Sister chromatid exchanges, indices of human chromosome damage and repair: Detection by fluorescence and induction by mitomycin C. Proc Natl Acad Sci USA 71: 3162-6
13. Lee PN. (2011). Summary of The epidemiological evidence relating snus to health. Regul Toxicol Pharmacol 59: 197-214
14. Levy DT, Mumford EA, Cummings KM, et al. (2004). The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. Cancer Epidemiol Biomarkers Prev 13: 2035-42
15. Lowe FJ, Gregg EO, McEwan M. (2009). Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers. Clin Chem Lab Med 47: 311-20
16. Lowe FJ, Luettich K, Gregg EO. (2013). Lung cancer biomarkers for The assessment of modified risk tobacco products: an oxidative stress perspective. Biomarkers 18: 183-95
17. Marano KM, Kathman SJ, Jones BA, et al. (2015). Study of cardiovascular disease biomarkers among tobacco consumers. Part 3: evaluation and comparison with The US National Health and Nutrition Examination Survey. Inhal Toxicol 27: 167-73
18. Marano KM, Naufal ZS, Borgerding MB, Potts RJ. (2012). Quantitative risk assessment of tobacco-burning and tobacco-heating cigarettes. Rec Adv Tob Sci 38: 3-20
19. Nordskog BK, Brown BG, Marano KM, et al. (2015). Study of cardiovascular disease biomarkers among tobacco consumers, part 2: biomarkers of biological effect. Inhal Toxicol 27: 157-66
20. Nutt DJ, Phillips LD, Balfour D, et al. (2014). Estimating The harms of nicotine-containing products using The MCDA approach. Eur Addict Res 20: 218-25
21. OECD. (1986). Genetic toxicology: in vitro sister chromatid exchange assay in mammalian cells. Paris: Organization for Economic Co-Operation and Development, 479
22. Ogden MW, Marano KM, Jones BA, Stiles MF. (2015a). Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: part 1. Study design and methodology. Biomarkers. [Epub ahead of print]. doi: 10.3109/1354750X.2015.1094133
23. Ogden MW, Marano KM, Jones BA, et al. (2015b). Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: part 2. Biomarkers of exposure. Biomarkers. [Epub ahead of print]. doi: 10.3109/1354750X.2015.1094134
24. Rennard SI, Daughton D, Fujita J, et al. (1990). Short-term smoking reduction is associated with reduction in measures of lower respiratory tract inflammation in heavy smokers. Eur Respir J 3: 752-9
25. Rennard SI, Umino T, Millatmal T, et al. (2002). Evaluation of subclinical respiratory tract inflammation in heavy smokers who switch to a cigarette-like nicotine delivery device that primarily heats tobacco. Nicotine Tob Res 4: 467-76
26. Roth HD, Roth AB, Liu X. (2005). Health risks of smoking compared to Swedish snus. Inhal Toxicol 17: 741-8
27. R.J. Reynolds Tobacco Company (RJRT) and American Snuff Company, LLC (ASC). (2011, July 28). Citizen petition. Available from: http://www.regulations.gov/# !documentDetail;D = FDA-2011-P-0573-0005 [last accessed 2 Aug 2014]
28. R.J. Reynolds Tobacco Company (RJRT). (2012, August 21). Supplement. Available from: http://www.regulations.gov/# !documentDetail;D = FDA-2011-P-0573-0006 [last accessed 2 Aug 2014]
29. Stratton K, Shetty P, Wallace R, Bondurant S. (2001). Clearing The smoke: The science base for tobacco harm reduction-executive summary. Tob Control 10: 189-95
30. Tonstad S, Cowan JL. (2009). C-reactive protein as a predictor of disease in smokers and former smokers: a review. Int J Clin Pract 63: 1634-41
31. US Department of Health and Human Services. (USDHHS). (2010). How tobacco smoke causes disease: The biology and behavioral basis for smoking-attributable disease: a report of The Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health
32. Wagner BM., Eclipse Expert Panel. (2000). A safer cigarette? A comparative study. A consensus report. Inhal Toxicol 12: 1-48
33. Yan W, Byrd GD, Ogden MW. (2006). Determination of isoprostanes in urine from smokers and never smokers by liquid chromatography tandem mass spectrometry. 54th Annual Conference on Mass Spectrometry and Allied Topics; 2006 May 28-June 1; Seattle, WA
34. Zeller M, Hatsukami D., Strategic Dialogue on Tobacco Harm Reduction Group. (2009). The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in The US. Tob Control 18: 324-32